Franklin Templeton Launches New ESG-Tilted ETFs in Europe
Franklin Templeton has launched an S&P 500 ETF and an S&P World ETF with ESG tilts in Europe.
The Franklin S&P 500 Screened UCITS ETF (SP5S) and Franklin S&P World Screened UCITS ETF (SPWR) are listed on Deutsche Borse and will list on the London Stock Exchange (LSE) and Euronext Paris on April 17 and Borsa Italiana on April 24, with total expense ratios (TERs) of 0.09% and 0.14%, respectively.
SP5S tracks the S&P 500 Guarded index, which offers exposure to large- and mid-cap US equities with an 'enhanced ESG profile.'
Meanwhile, SPWR tracks the S&P Guarded World index, capturing large- and mid-cap global equities with an identical ESG screen.
Both ETFs exclude companies involved in specific business activities, environmental, social and governance controversies or those that violate UN Global Compact principles and are classified as Article 8 under the Sustainable Finance Disclosure Regulation (SFDR).
Caroline Baron (pictured), head of ETF distribution, EMEA, at Franklin Templeton, said, 'These ETFs would be suitable for investors looking to invest in core exposures that are article 8 compliant and those seeking a tight tracking versus the traditional benchmarks, such as S&P 500 and S&P World.
'These ETFs could be used with traditional core solutions to complement them for example.'
The launches come after the European Securities and Markets Authority (ESMA) updated its guidelines on ESG fund naming rules, with many issuers either stripping the moniker from existing ETFs or changing the methodology to comply with the updated guidelines.
This article was originally published at etf.com sister publication ETF Stream.Permalink | © Copyright 2025 etf.com. All rights reserved
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
41 minutes ago
- CNBC
Asia-Pacific markets set to open mixed as investors assess Trump's 'done' deal with China
Hong Kong. Kowloon. Busy street in Mong Kok District. Acavalli | E+ | Getty Images Asia-Pacific markets were set to open mixed as traders assessed U.S. President Donald Trump's declaration that a trade deal with China was "done." Chinese imports would invite 55% tariffs, Trump suggested. Commerce Secretary Howard Lutnick confirmed that tariffs on China will stay at that level. Japan's benchmark Nikkei 225 was set to open lower, with the futures contract in Chicago at 38,330 while its counterpart in Osaka last traded at 38,400 compared with the index's last close of 38,421.19. Futures for Hong Kong's Hang Seng index last traded at 24,252, pointing to a weaker open compared to the HSI's last close of 24,366.94. Australia's S&P/ASX 200 was set to start the day higher, with futures tied to the benchmark at 8,622, compared to the index's close of 8,592.1 in the previous session. Traders will be looking toward a slate of inflation data coming out of the Philippines and Thailand later in the day. U.S. stock futures fell as traders weighed a preliminary U.S.-China trade agreement and new inflation data. S&P 500 futures traded down 0.2%, along with Nasdaq 100 futures. Futures tied to the Dow Jones Industrial Average were also lower by 72 points, or 0.2%. These moves come after U.S. consumer prices rose less than expected in Ma. The consumer price index climbed 0.1% for the month, compared with the Dow Jones forecast for a 0.2% rise. Core CPI, which excludes food and energy prices, also rose less than expected. Overnight stateside, all three key benchmarks closed lower. The market's recent run higher took a breather as major indexes ended the session near previous closing levels. Trump said earlier in a Truth Social post that the deal with China was "done, subject to final approval with President Xi and me." As part of the deal framework, he said that magnets and "any necessary rare earths" will be supplied up front by China and the U.S. will allow Chinese students to attend U.S. colleges and universities, adding that "WE ARE GETTING A TOTAL OF 55% TARIFFS, CHINA IS GETTING 10%." — CNBC's Brian Evans, Pia Singh, Sean Conlon contributed to this report. U.S. crude oil futures rose more than 4% Wednesday on escalating tensions in the Middle East. Brent crude futures rose $2.90, or 4.34%, to close at $69.77 barrel. U.S. West Texas Intermediate crude gained $3.17, or 4.88%, to settle at $68.15. The U.S. is preparing a partial evacuation of its embassy in Iraq due to heightened security risks in the region, sources told Reuters. The U.S. military has authorized the "voluntary departure" of troops' dependents from the Middle East due to rising tensions with Iran, sources told the Associated Press. — Spencer Kimball The widely followed $39 billion 10-year Treasury auction provided some relief to investors who have been worried about global demand for the government asset. The yield of 4.221% came in 7 basis points below the level when issued. Meanwhile, the level of direct and indirect bidding took control 91% of the auction, a similar pace last month but the most since February 2023, according to Peter Boockvar, chief investment officer of Bleakley Financial Group. However, the bid to cover of 2.52 came in below the previous 12 month average of 2.57, marking the second weakest since October 2024. "The 10 yr note auction was somewhat of a mixed bag but more good than not," Boockvar said. Nonetheless, BMO's called the auction a "strong" one as demand Treasurys remains solid in the uncertain macro environment. — Yun Li
Yahoo
43 minutes ago
- Yahoo
Stock market today: Dow, S&P 500, Nasdaq futures slip as investors assess easing trade tensions
US stock futures slipped as Wall Street assessed easing tensions between the US and key trading partners as well as softening inflation. Futures attached to the Dow Jones Industrial Average (YM=F) dipped 0.1%. Futures attached to the benchmark S&P 500 (ES=F) and the tech-heavy Nasdaq 100 (NQ=F) fell 0.2%. On Wednesday, Treasury Secretary Scott Bessent told Congress it is "highly likely" that countries engaging in trade negotiations with the US would see an extension of a tariff pause that is already in place on President Trump's most sweeping duties. Bessent's comment came after he returned from London on Tuesday, where representatives from US and China announced the countries had agreed to a proposal that would address critical trade disputes. Read more: The latest on Trump's tariffs Stocks wobbled during the day Wednesday amid the evolving trade news as well as the latest Consumer Price Index (CPI) report, which showed easing inflation pressures. The data puts the Federal Reserve in a tight spot ahead of its policy meeting next week, though analysts expect officials to maintain their wait-and-see approach to interest rate cuts as tariff uncertainty lingers. On Thursday, investors will receive fresh data on wholesale inflation with the release of the Producer Price Index (PPI) report. As earnings season wraps up, Adobe (ADBE) will also share its results. Sign in to access your portfolio
Yahoo
44 minutes ago
- Yahoo
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26
Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential. It reported interim Week 26 data from its Phase 2 COACH Trial, confirming that combining TransCon hGH (lonapegsomatropin) with TransCon CNP (navepegritide) raised annualized growth velocity (AGV) and height Z-scores in children with achondroplasia. A close-up view of a hand manipulating a syringe while delivering TransCon CNP into a tumor. A mean AGV of 9.14 cm/year and a +0.53 Z-score rise were attained by treatment-naïve youngsters (N=12). Children (N=9) treated with TransCon CNP in the past achieved an AGV of 8.25 cm/year with a +0.44 Z-score improvement. The majority of side effects were modest, and safety remained consistent with monotherapies. The COACH Trial is the first to assess this combination in kids between the ages of two and eleven. While TransCon CNP is undergoing FDA priority review, TransCon hGH is approved as SKYTROFA® for juvenile growth hormone insufficiency. The treatment focuses on the FGFR3-CNP signaling imbalance that is at the heart of achondroplasia, a disorder that affects more than 250,000 people worldwide. It is anticipated that the results of week 52 and a scheduled Phase 3 trial in Q4 2025 will further clarify efficacy and long-term benefits. The biopharmaceutical business Ascendis Pharma A/S (NASDAQ:ASND) uses its TransCon technology platform to significantly improve patient outcomes. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.
